HC Wainwright Brokers Reduce Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Eton Pharmaceuticals in a report issued on Tuesday, August 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.15. HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is $0.75 per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at $0.52 EPS, Q1 2027 earnings at $0.26 EPS, Q2 2027 earnings at $0.30 EPS, Q3 2027 earnings at $0.36 EPS and Q4 2027 earnings at $0.35 EPS.

Other analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Canaccord Genuity Group assumed coverage on Eton Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $60.00 price objective on the stock. Wall Street Zen upgraded Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Zacks Research lowered Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Finally, Craig Hallum upped their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Eton Pharmaceuticals Price Performance

Shares of ETON stock opened at $42.05 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The company has a market capitalization of $1.15 billion, a P/E ratio of -600.63 and a beta of 0.86. The company’s 50-day simple moving average is $37.95 and its two-hundred day simple moving average is $28.01. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $50.18.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The company had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ETON. Quarry LP purchased a new stake in shares of Eton Pharmaceuticals during the third quarter valued at about $37,000. Legal & General Group Plc bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals in the fourth quarter valued at approximately $74,000. Finally, Persistent Asset Partners Ltd purchased a new position in Eton Pharmaceuticals in the second quarter worth $90,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total transaction of $619,298.13. Following the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $794,586.03. This trade represents a 43.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is owned by company insiders.

Key Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $65 price target, implying meaningful upside from recent trading levels. The analyst projects improving EPS through 2027, reaching $0.26 in Q1, $0.30 in Q2, $0.36 in Q3 and $0.35 in Q4 2027.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. Because the data appears incomplete or anomalous, it provides little useful signal about investor positioning.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q2 2026 to $0.11 from $0.15, Q3 2026 to $0.17 from $0.23, Q4 2026 to $0.19 from $0.25, and full-year 2026 to $0.52 from $0.68. These cuts suggest a slower earnings ramp and are likely the main factor weighing on ETON.
• Negative Sentiment: The revised FY2026 estimate of $0.52 is also below the broader current-year consensus estimate of $0.75 per share, increasing concern that near-term results may fall short of expectations.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.